Skip to main content

Table 2 Relationship between JCV positivity and MRI and clinical outcomes

From: May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study

Endpoint JCV- JCV+ p-value
ARR on 24 months 0.10 ± 0.25 0.083 ± 0.24 0.82
New T2 lesions at 24 months 5.6 ± 9.1 9.5 ± 14.9 0.23
Disability progression, n (%) 3/73 (4.1) 6/68 (8.8) 0.31
  1. Results are reported as mean ± SD except where differently stated